Æterna Zentaris P/E
Cos'è P/E di Æterna Zentaris?
P/E di Æterna Zentaris, Inc. è N/A
Qual è la definizione di P/E?
Il rapporto prezzo / utili è il rapporto tra il prezzo delle azioni di una società e l'utile per azione della società calcolato su dodici mesi.
The price to earnings ratio is the most widely used method for determining whether shares are accurately valued in relation to one another. But the P/E ratio does not in itself indicate whether the share is a bargain. The P/E ratio depends on the market’s perception of the risk and future growth in earnings. A company with a low P/E ratio indicates that the market perceives it as a higher risk or a lower growth or both as compared to a company with a higher price to earnings ratio. The P/E ratio of a listed company’s stock is the result of the collective perception of the market as to how risky the company is and what its earnings growth prospects are in relation to that of other companies. Investors use the P/E ratio to compare their own perception of the risk and growth of a company against the market’s collective perception of the risk and growth as reflected in the current P/E ratio.
P/E di aziende nel Health Care settore su TSX rispetto a Æterna Zentaris
Cosa fa Æterna Zentaris?
Aeterna Zentaris Inc., a specialty biopharmaceutical company, engages in developing and commercializing therapeutics and diagnostic tests. Its lead product is macimorelin, an orally available peptidomimetic ghrelin receptor (GHSR-1a) agonist that stimulates the secretion of growth hormone by binding to the GHSR-1a for the diagnosis of adult growth hormone deficiency and childhood-onset growth hormone deficiency, as well as oncology indications. The company markets macimorelin under the Macrilen brand name. Aeterna Zentaris Inc. has a license agreement with University Wuerzburg to research, develop, manufacture, and sell a potential COVID-19 vaccine; development, manufacture, and commercialization of the treatment for neuromyelitis optica spectrum disorder; and to develop human 3D intestinal tissue models to study infection biology; and for pre-clinical development towards the potential treatment of Parkinson's disease. It also has a license agreement with Consilient Health Ltd., Novo Nordisk Novo Nordisk Health Care AG, and NK MEDITECH Ltd. for the development and commercialization of macimorelin in the United States and Canada, as well as The University of Sheffield, the United Kingdom for the research, development, manufacture, and commercialization of parathyroid hormone fusion polypeptides for the treatment of primary hypoparathyroidism. Aeterna Zentaris Inc. was incorporated in 1990 and is headquartered in Summerville, South Carolina.
Aziende con p/e simili a Æterna Zentaris
- GOLO Mobile ha P/E di N/A
- Red River Capital ha P/E di N/A
- ContextLogic Inc ha P/E di N/A
- Urban One Inc ha P/E di N/A
- Alliance Mining ha P/E di N/A
- Flamingo AI ha P/E di N/A
- Æterna Zentaris ha P/E di N/A
- Immutep ha P/E di N/A
- SEM ha P/E di N/A
- Antibe Therapeutics ha P/E di N/A
- Ayr Strategies ha P/E di N/A
- YANGAROO ha P/E di N/A
- Delcath Systems ha P/E di N/A